Communiqués Biostax Corp.

Actions

BTAX

US45252A3059

Marché Fermé - OTC Markets Autres places de cotation 17:33:59 03/06/2024			Varia. 5j.	Varia. 1 janv.
0,0425 ^USD	+21,40%		0,00%	-41,78%

20/05	Biostax Corp. présente ses résultats pour le premier trimestre clos le 31 mars 2024	CI
16/04	Biostax Corp. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception	30/11	AQ
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro	15/11	AQ
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors	02/11	AQ
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment	24/10/23	AQ
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky	14/09/23	AQ
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV	29/08/23	AQ
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH	15/08/23	AQ
Biostax Launches Growth Funding Round to Revitalize Affordable Healthcare	30/05/23	PR
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies	20/04/23	AQ
IMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	20/04/23	AQ
IMMUNE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	10/04/23	AQ
IMMUNE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	06/03/23	AQ
Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction	01/03/23	AQ
IMMUNE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	03/01/23	AQ
IMMUNE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q)	14/11/22	AQ
IMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	09/11/22	AQ
Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development	09/11/22	AQ
IMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	12/10/22	AQ
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors	27/09/22	AQ
IMMUNE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	27/09/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Biostax Corp.

Actions

BTAX

US45252A3059

Communiqués

Filtres